AbbVie Close to Deal for Cancer Drugmaker RevMed, WSJ Says
AbbVie Inc. is in “advanced” talks to purchase Revolution Medicines Inc., a cancer focused biotech, in a deal that could be worth more than $20 billion, according to a report in the Wall Street Journal, citing people familiar with the matter.
The biotech was valued at more than $16 billion as of Wednesday afternoon.